Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis

Overview of attention for article published in PLOS Medicine, August 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

news: 3 news outlets
policy: 1 policy source

twitter: 4 X users

Readers on

mendeley: 131 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Cost-effectiveness of Herceptin for early stage breast cancer varies by age and tumour type

MedicalXpress, 26 Oct 2016

A new study from the University of Otago, Wellington (UOW) found that the cost-effectiveness of the drug trastuzumab (known…

News story from New Zealand Doctor on Tuesday 25 October 2016

New Zealand Doctor, 25 Oct 2016

Cost-effectiveness of Herceptin® for breast cancer

Scoop, 25 Oct 2016

Cost-effectiveness of Herceptin® for early stage breast cancer varies by age and tumour type A new study from the University of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.